Brainstorm Cell Therapeutics Inc BCLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BCLI is a good fit for your portfolio.
News
-
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
-
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
-
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
-
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
-
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
-
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
-
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn
-
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Trading Information
- Previous Close Price
- $0.37
- Day Range
- $0.35–0.38
- 52-Week Range
- $0.13–1.90
- Bid/Ask
- $0.35 / $0.36
- Market Cap
- $27.98 Mil
- Volume/Avg
- 141,860 / 629,629
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.brainstorm-cell.com
Comparables
Valuation
|
Metric
|
BCLI
|
KROS
|
MORF
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 4.16 | 4.58 |
Price/Sales | — | 6,992.78 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BCLI
|
KROS
|
MORF
|
|---|---|---|---|
Quick Ratio | 0.12 | 23.73 | 23.71 |
Current Ratio | 0.18 | 24.74 | 24.13 |
Interest Coverage | −28.53 | — | — |
Quick Ratio
BCLI
KROS
MORF
Profitability
|
Metric
|
BCLI
|
KROS
|
MORF
|
|---|---|---|---|
Return on Assets (Normalized) | −258.37% | −33.58% | −20.07% |
Return on Equity (Normalized) | — | −36.62% | −20.72% |
Return on Invested Capital (Normalized) | — | −35.21% | −24.50% |
Return on Assets
BCLI
KROS
MORF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Yznymmyg | Wpcd | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sjpqrnht | Smlrgb | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zrpmfxbw | Rrpzlzx | $118.7 Bil | |||
| Moderna Inc
MRNA
| Zhqjrqxcv | Zvlg | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mnslnhdv | Mckqhvj | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Jygglpw | Bgb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Xbcmvhdj | Ldsqn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rfkfxqfxr | Fdzwqn | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Mfhkfqpb | Yhvn | $15.0 Bil | |||
| Incyte Corp
INCY
| Rqcwqmhf | Fvsvxj | $13.5 Bil |